ONWARD Medical Announces Release of 2024 Annual Report
ONWARD Medical N.V. (Euronext: ONWD), a medical technology company specializing in spinal cord stimulation therapies, has filed its 2024 Annual Report with the Dutch Authority for the Financial Markets (AFM). The company, which focuses on restoring movement and independence for people with spinal cord injury (SCI), has also published its 2024 Sustainability Report.
The company received recognition for its sustainability efforts in 2024, earning a silver medal from EcoVadis, the world's largest business sustainability ratings provider. CEO Dave Marver described 2024 as a transformative year for ONWARD in advancing their mission.
Stakeholders can access the 2024 Annual Report, Sustainability Summary, and a recording of the 2024 Full Year Results Webinar from April 1, 2025, on the company's Investor Relations webpage.
ONWARD Medical N.V. (Euronext: ONWD), un'azienda di tecnologia medica specializzata in terapie di stimolazione del midollo spinale, ha depositato il suo Rapporto Annuale 2024 presso l'Autorità olandese per i mercati finanziari (AFM). L'azienda, che si concentra sul recupero del movimento e dell'indipendenza per le persone con lesione del midollo spinale (SCI), ha anche pubblicato il suo Rapporto sulla Sostenibilità 2024.
Nel 2024, l'azienda ha ricevuto un riconoscimento per i suoi sforzi in ambito sostenibile, ottenendo una medaglia d'argento da EcoVadis, il più grande fornitore mondiale di valutazioni sulla sostenibilità aziendale. Il CEO Dave Marver ha definito il 2024 un anno di trasformazione per ONWARD nel progresso della loro missione.
Gli stakeholder potranno accedere al Rapporto Annuale 2024, al Sommario sulla Sostenibilità e alla registrazione del Webinar sui Risultati dell'intero anno 2024 a partire dal 1° aprile 2025, sulla pagina Investor Relations dell'azienda.
ONWARD Medical N.V. (Euronext: ONWD), una empresa de tecnología médica especializada en terapias de estimulación de la médula espinal, ha presentado su Informe Anual 2024 ante la Autoridad Holandesa para los Mercados Financieros (AFM). La compañía, que se enfoca en restaurar el movimiento y la independencia de personas con lesión medular (SCI), también ha publicado su Informe de Sostenibilidad 2024.
En 2024, la empresa recibió reconocimiento por sus esfuerzos en sostenibilidad, obteniendo una medalla de plata de EcoVadis, el mayor proveedor mundial de calificaciones de sostenibilidad empresarial. El CEO Dave Marver describió 2024 como un año transformador para ONWARD en el avance de su misión.
Los interesados podrán acceder al Informe Anual 2024, al Resumen de Sostenibilidad y a la grabación del Webinar de Resultados del año completo 2024 a partir del 1 de abril de 2025, en la página de Relaciones con Inversores de la compañía.
ONWARD Medical N.V. (유로넥스트: ONWD)는 척수 자극 치료를 전문으로 하는 의료 기술 회사로, 네덜란드 금융시장청(AFM)에 2024년 연례 보고서를 제출했습니다. 척수 손상(SCI)을 가진 사람들의 움직임과 독립성을 회복하는 데 중점을 둔 이 회사는 2024년 지속가능성 보고서도 함께 발표했습니다.
2024년, 회사는 세계 최대 기업 지속가능성 평가 기관인 EcoVadis로부터 은메달을 수상하며 지속가능성 노력에 대한 인정을 받았습니다. CEO 데이브 마버는 2024년을 ONWARD의 사명을 진전시키는 변혁의 해로 평가했습니다.
이해관계자들은 2025년 4월 1일부터 회사의 투자자 관계 웹페이지에서 2024년 연례 보고서, 지속가능성 요약, 2024년 전체 실적 웨비나 녹화를 열람할 수 있습니다.
ONWARD Medical N.V. (Euronext : ONWD), une entreprise de technologie médicale spécialisée dans les thérapies de stimulation de la moelle épinière, a déposé son rapport annuel 2024 auprès de l'Autorité néerlandaise des marchés financiers (AFM). L'entreprise, qui se concentre sur la restauration du mouvement et de l'autonomie des personnes atteintes de lésions de la moelle épinière (SCI), a également publié son rapport de durabilité 2024.
En 2024, l'entreprise a été reconnue pour ses efforts en matière de durabilité, obtenant une médaille d'argent d'EcoVadis, le plus grand fournisseur mondial d'évaluations de durabilité des entreprises. Le PDG Dave Marver a qualifié 2024 d'année de transformation pour ONWARD dans l'avancement de leur mission.
Les parties prenantes pourront accéder au rapport annuel 2024, au résumé sur la durabilité ainsi qu'à l'enregistrement du webinaire des résultats annuels 2024 à partir du 1er avril 2025, sur la page Relations Investisseurs de l'entreprise.
ONWARD Medical N.V. (Euronext: ONWD), ein Medizintechnikunternehmen, das sich auf Therapien zur Rückenmarkstimulation spezialisiert hat, hat seinen Jahresbericht 2024 bei der niederländischen Finanzmarktaufsicht (AFM) eingereicht. Das Unternehmen, das sich auf die Wiederherstellung von Bewegung und Unabhängigkeit bei Menschen mit Rückenmarksverletzungen (SCI) konzentriert, hat außerdem seinen Nachhaltigkeitsbericht 2024 veröffentlicht.
Im Jahr 2024 wurde das Unternehmen für seine Nachhaltigkeitsbemühungen anerkannt und erhielt eine Silbermedaille von EcoVadis, dem weltweit größten Anbieter von Nachhaltigkeitsbewertungen für Unternehmen. CEO Dave Marver bezeichnete 2024 als ein transformierendes Jahr für ONWARD bei der Verwirklichung ihrer Mission.
Interessierte können ab dem 1. April 2025 den Jahresbericht 2024, die Nachhaltigkeitszusammenfassung und die Aufzeichnung des Webinars zu den Gesamtergebnissen 2024 auf der Investor-Relations-Webseite des Unternehmens abrufen.
- Received silver medal recognition from EcoVadis for sustainability performance
- None.
EINDHOVEN, the Netherlands, April 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that its Annual Report for the fiscal year ended December 31, 2024 has been filed with the Dutch Authority for the Financial Markets (AFM).
The Company has also released its 2024 Sustainability Report. Last year, the Company was awarded a silver medal by EcoVadis, the world’s largest provider of business sustainability ratings.
"2024 was transformative for ONWARD as we advanced our mission to restore movement, function, and independence for people with spinal cord injury," said Dave Marver, Chief Executive Officer. "We are pleased to share our progress and financial results with our stakeholders through our Annual Report."
The 2024 Annual Report, 2024 Sustainability Summary, and a recording of the 2024 Full Year Results Webinar held on April 1, 2025 can be viewed by visiting the Company’s Investor Relations webpage.
About ONWARD Medical
ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with SCI and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company’s ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).
For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.
To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.
For Media Inquiries:
media@onwd.com
For Investor Inquiries:
investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
FAQ
What key developments did ONWARD Medical (ONWRY) report in its 2024 Annual Report?
Where can investors access ONWARD Medical's (ONWRY) 2024 financial results and reports?
What sustainability recognition did ONWARD Medical (ONWRY) receive in 2024?
What regulatory filing did ONWARD Medical (ONWRY) complete with the AFM for 2024?
